Assembly Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights
05 November 2021 - 7:05AM
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage
biotechnology company developing innovative therapeutics targeting
hepatitis B virus (HBV), today reported financial results and
recent highlights for the third quarter ended September 30, 2021.
John McHutchison, AO, MD, chief executive officer and president
of Assembly Bio, said, “We are excited to advance our latest
core inhibitor ABI-4334, with a potential best-in-class profile,
and we are working quickly and diligently to move this candidate
into clinical development as soon as possible next year. In
parallel, we have expanded evaluation of triple combination
regimens to treat HBV, which include the potential backbone therapy
of our lead investigational core inhibitor candidate vebicorvir
(VBR) plus standard-of-care nucleos(t)ide reverse transcriptase
inhibitor (Nrtl) therapy together with an additional complementary
mechanism. Our two ongoing Phase 2 studies include interferon
(peg-IFNα) and Arbutus’ RNAi therapeutic candidate, and we look
forward to initiating a third Phase 2, all-oral triple combination
cohort with Antios’ ASPIN, ATI-2173. We anticipate initial data
from all three of these studies during 2022. Meanwhile, we are
pleased to feature our science and portfolio at scientific and
clinical meetings, demonstrating our commitment to pursuing finite
and curative therapies for the more than a quarter of a billion
individuals living with chronic HBV infection worldwide.”
Recent Updates
- ABI-4334, a next-generation core inhibitor candidate that has
been optimized for potency against the formation of cccDNA, was
selected for advancement into clinical development. The company is
conducting preclinical work, with the aim of completing regulatory
filings and initiating a clinical study as soon as possible in
2022.
- Enrollment and dosing continue in two Phase 2 triple
combination studies evaluating Assembly Bio’s lead core inhibitor
candidate, VBR + Nrtl therapy along with Arbutus Biopharma’s RNAi
therapeutic candidate, AB-729, and separately with peg-IFNα.
- A clinical collaboration agreement was announced with Antios
Therapeutics to evaluate a triple combination of VBR + NrtI and
ATI-2173, Antios’ investigational proprietary active site
polymerase inhibitor nucleotide (ASPIN) in a ten patient
cohort.
- Further development of ABI-H2158 (2158) was discontinued
following the observation of elevated alanine aminotransferase
(ALT) levels consistent with drug-induced hepatotoxicity in a Phase
2 trial. The decision reflects the company’s strategy of advancing
the candidates that exhibit the strongest safety and efficacy
profiles for later-stage clinical studies.
- William Delaney, PhD, chief scientific officer, highlighted
Assembly Bio’s approach and core inhibitor portfolio during recent
scientific conferences focused on HBV.
- Participated in a round-table discussion during ICE-HBV: HBV
Cure: The Mechanisms Behind Combination Therapies
- Presented on the “Discovery and Development of Novel Inhibitors
of HBV Core Protein for the Treatment for Chronic Hepatitis B”
during The Science of HBV Cure Meeting 2021
Anticipated Milestones and Events
- Interim on-treatment data from triple combination studies with
VBR + NrtI, and complementary mechanisms RNAi and peg-IFNα
anticipated during 2022
- Initiate triple combination cohort with VBR + NrtI and ATI-2173
in H1 2022 with 12-week on-treatment data expected by year-end
2022
- Initiate Phase 1b study in ABI-H3733 in 2022
- Complete regulatory filings for ABI-4334 and initiate clinical
development during 2022
Upcoming Conferences
- Three abstracts, including one late-breaking submission, will
be presented at the annual meeting of the American Association for
the Study of Liver Diseases (AASLD), The Liver Meeting Digital
Experience™ (TLMdX), being hosted virtually November 12-15,
2021
- Luisa Stamm, MD, PhD, chief medical officer, will present
during the International Workshop on HBV Cure 2021, November 10,
2021 at 11 am ET
- Jefferies London Healthcare Conference. A webcast of the
fireside chat will be available in the “Events and Presentations”
page in the “Investors” section of the company’s website at
www.assemblybio.com on November 18, 2021 at 8:00 am GMT
- William Delaney, PhD, chief scientific officer, will present
“Development of HBV Core Inhibitors for the treatment of Chronic
Hepatitis B Infection” during HEP DART 2021, December 7, 2021
at 5:45 - 7:30 pm MST
Third Quarter 2021 Financial Results
- Cash, cash equivalents and marketable
securities were $190.1 million as of September 30,
2021, compared to $199.1 million as of June 30, 2021. This result
includes the $10.1 million of net proceeds from the issuance of
common shares under Assembly Bio’s at-the-market (ATM) program. The
company’s cash position is projected to fund operations into the
second half of 2023.
- Revenues from collaborative research were
$6.3 million for the three months ended September 30, 2021,
compared to $34.6 million for the same period in 2020. Revenue for
the three months ended September 30, 2021, consists of deferred
revenue allocated to 2158 under the collaboration agreement with
BeiGene following the announcement that Assembly Bio discontinued
development of the candidate. The decrease year-over-year is due to
the recognition of the amount allocated to VBR as revenue in Q3
2020 upon entering into the BeiGene agreement as well as the
termination of the microbiome collaboration agreement with Allergan
following AbbVie Inc.’s acquisition of Allergan. In Q1 2021
Assembly Bio completed the wind-down of its microbiome
program.
- Research and development expenses were
$18.5 million for the three months ended September 30, 2021,
compared to $26.9 million for the same period in 2020. The decrease
is primarily due to a decrease of $8.3 million related to the
wind-down of the microbiome program. Research and development
expenses include non-cash stock-based compensation expenses of $1.1
million for the three months ended September 30, 2021, and $2.8
million for the same period in 2020. The decrease is primarily due
to a decrease in the fair value of equity grants as well as a
decrease in headcount and outstanding awards resulting from the
wind-down of the microbiome program.
- General and administrative expenses were
$6.7 million for the three months ended September 30, 2021,
compared to $11.7 million for the same period in 2020. General and
administrative expenses include non-cash stock-based compensation
expenses of $0.5 million for the three months ended September 30,
2021, and $3.3 million for the same period in 2020. The decrease is
due to a decrease in the fair value of equity grants as well as a
reversal of previously recognized expenses related to the forfeited
awards to a former officer.
- Net loss attributable to common
stockholders was $18.8 million, or $0.41 per basic
and diluted share, for the three months ended September 30, 2021,
compared to $3.3 million, or $0.09 per basic and diluted share, for
the same period in 2020. The increase was due to less revenue being
recognized under the company’s collaboration agreements to offset
expenses in 2021.
About Assembly BiosciencesAssembly Bio is
a clinical-stage biotechnology company committed to bringing finite
and curative therapies to the 270 million people living with
hepatitis B virus (HBV) worldwide. A pioneer in the development of
a new class of potent, oral core inhibitor drug candidates,
Assembly Bio’s approach aims to break the complex viral replication
cycle of HBV to free patients from a lifetime of therapy. Assembly
Bio’s strategy toward cure includes a leading portfolio of more
potent, next-generation core inhibitors, proof-of-concept
combination studies and a research program focused on the discovery
of novel HBV targets. For more information,
visit assemblybio.com.
Forward-Looking StatementsThe information in
this press release contains forward-looking statements that are
subject to certain risks and uncertainties that could cause actual
results to materially differ. These risks and uncertainties
include: Assembly Bio’s ability to initiate and complete
clinical studies involving its HBV therapeutic product candidates,
including studies contemplated by Assembly Bio’s clinical
collaboration agreements, in the currently anticipated timeframes;
safety and efficacy data from clinical studies may not warrant
further development of Assembly Bio’s product candidates; clinical
and nonclinical data presented at conferences may not differentiate
Assembly Bio’s product candidates from other companies’ candidates;
results of nonclinical studies may not be representative of disease
behavior in a clinical setting and may not be predictive of the
outcomes of clinical studies; continued development and
commercialization of Assembly Bio’s HBV product candidates, if
successful, in the China territory will be dependent on, and
subject to, Assembly Bio’s collaboration agreement governing its
activity in the China territory; Assembly Bio’s ability to maintain
financial resources necessary to continue its clinical studies and
fund business operations; any impact that the COVID-19 pandemic may
have on Assembly Bio’s business and operations, including
initiation and continuation of its clinical studies or timing of
discussions with regulatory authorities; and other risks identified
from time to time in Assembly Bio’s reports filed with
the U.S. Securities and Exchange
Commission (the SEC). You are urged to consider
statements that include the words may, will, would, could, should,
might, believes, hopes, estimates, projects, potential, expects,
plans, anticipates, intends, continues, forecast, designed, goal or
the negative of those words or other comparable words to be
uncertain and forward-looking. Assembly Bio intends such
forward-looking statements to be covered by the safe harbor
provisions contained in Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. More information about Assembly Bio’s risks and
uncertainties are more fully detailed under the heading “Risk
Factors” in Assembly Bio’s filings with the SEC, including its
most recent Annual Report on Form 10-K, Quarterly Reports on Form
10-Q and Current Reports on Form 8-K. Except as required by law,
Assembly Bio assumes no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
ContactsInvestor and Corporate:Lauren
GlaserSenior Vice President, Investor Relations and Corporate
Affairs(415) 521-3828lglaser@assemblybio.com
Media:Sam Brown Inc. Audra Friis (917)
519-9577 ASMBMedia@sambrown.com
|
|
ASSEMBLY BIOSCIENCES, INC. |
CONDENSED CONSOLIDATED BALANCE SHEETS |
(In thousands except for share amounts and par value) |
|
|
|
|
|
|
|
September 30, |
|
December 31, |
|
|
|
2021 |
|
|
|
2020 |
|
|
|
(Unaudited) |
|
|
ASSETS |
|
|
|
|
Current assets |
|
|
|
|
Cash and cash equivalents |
|
$ |
70,760 |
|
|
$ |
59,444 |
|
Marketable securities - short-term |
|
|
110,142 |
|
|
|
156,969 |
|
Accounts receivable from collaborations |
|
|
769 |
|
|
|
1,230 |
|
Prepaid expenses and other current assets |
|
|
6,548 |
|
|
|
6,850 |
|
Total current assets |
|
|
188,219 |
|
|
|
224,493 |
|
|
|
|
|
|
Marketable securities - long-term |
|
|
9,180 |
|
|
|
— |
|
Property and equipment, net |
|
|
1,241 |
|
|
|
1,600 |
|
Operating lease right-of-use (ROU) assets |
|
|
6,773 |
|
|
|
9,131 |
|
Other assets |
|
|
1,922 |
|
|
|
6,392 |
|
Indefinite-lived intangible asset |
|
|
29,000 |
|
|
|
29,000 |
|
Goodwill |
|
|
12,638 |
|
|
|
12,638 |
|
Total assets |
|
$ |
248,973 |
|
|
$ |
283,254 |
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
Current liabilities |
|
|
|
|
Accounts payable |
|
$ |
2,628 |
|
|
$ |
4,598 |
|
Accrued clinical expenses |
|
|
3,744 |
|
|
|
4,444 |
|
Other accrued expenses |
|
|
5,457 |
|
|
|
11,987 |
|
Operating lease liabilities - short-term |
|
|
3,099 |
|
|
|
3,404 |
|
Total current liabilities |
|
|
14,928 |
|
|
|
24,433 |
|
|
|
|
|
|
Deferred tax liabilities |
|
|
2,531 |
|
|
|
2,531 |
|
Deferred revenue |
|
|
2,733 |
|
|
|
8,987 |
|
Operating lease liabilities - long-term |
|
|
4,136 |
|
|
|
6,725 |
|
Total liabilities |
|
|
24,328 |
|
|
|
42,676 |
|
|
|
|
|
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
|
Stockholders' equity |
|
|
|
|
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no
shares issued or outstanding |
|
|
— |
|
|
|
— |
|
Common stock, $0.001 par value; 100,000,000 shares authorized as of
September 30, 2021 and December 31, 2020; 47,077,052 and
34,026,680 shares issued and outstanding as of September 30,
2021 and December 31, 2020, respectively |
|
|
47 |
|
|
|
34 |
|
Additional paid-in capital |
|
|
796,057 |
|
|
|
742,387 |
|
Accumulated other comprehensive loss |
|
|
(288 |
) |
|
|
(270 |
) |
Accumulated deficit |
|
|
(571,171 |
) |
|
|
(501,573 |
) |
Total stockholders' equity |
|
|
224,645 |
|
|
|
240,578 |
|
Total liabilities and stockholders' equity |
|
$ |
248,973 |
|
|
$ |
283,254 |
|
|
|
|
|
|
ASSEMBLY BIOSCIENCES, INC. |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE LOSS |
(In thousands except for share and per share amounts) |
(Unaudited) |
|
|
|
|
|
|
|
|
|
|
|
Three Months EndedSeptember 30, |
|
Nine Months EndedSeptember 30, |
|
|
|
2021 |
|
|
|
2020 |
|
|
|
2021 |
|
|
|
2020 |
|
Collaboration revenue |
|
$ |
6,254 |
|
|
$ |
34,611 |
|
|
$ |
6,254 |
|
|
$ |
78,068 |
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
Research and development |
|
|
18,474 |
|
|
|
26,941 |
|
|
|
53,777 |
|
|
|
73,314 |
|
General and administrative |
|
|
6,655 |
|
|
|
11,689 |
|
|
|
22,276 |
|
|
|
29,888 |
|
Total operating expenses |
|
|
25,129 |
|
|
|
38,630 |
|
|
|
76,053 |
|
|
|
103,202 |
|
Loss from operations |
|
|
(18,875 |
) |
|
|
(4,019 |
) |
|
|
(69,799 |
) |
|
|
(25,134 |
) |
|
|
|
|
|
|
|
|
|
Other income: |
|
|
|
|
|
|
|
|
Interest and other income, net |
|
|
72 |
|
|
|
670 |
|
|
|
201 |
|
|
|
2,400 |
|
Total other income |
|
|
72 |
|
|
|
670 |
|
|
|
201 |
|
|
|
2,400 |
|
Net loss |
|
$ |
(18,803 |
) |
|
$ |
(3,349 |
) |
|
$ |
(69,598 |
) |
|
$ |
(22,734 |
) |
|
|
|
|
|
|
|
|
|
Other comprehensive (loss) income |
|
|
|
|
|
|
|
|
Unrealized (loss) gain on marketable securities |
|
|
(15 |
) |
|
|
(262 |
) |
|
|
(18 |
) |
|
|
43 |
|
Comprehensive loss |
|
$ |
(18,818 |
) |
|
$ |
(3,611 |
) |
|
$ |
(69,616 |
) |
|
$ |
(22,691 |
) |
|
|
|
|
|
|
|
|
|
Net loss per share, basic and diluted |
|
$ |
(0.41 |
) |
|
$ |
(0.09 |
) |
|
$ |
(1.63 |
) |
|
$ |
(0.64 |
) |
Weighted average common shares outstanding, basic and diluted |
|
|
45,569,276 |
|
|
|
35,506,042 |
|
|
|
42,725,109 |
|
|
|
35,321,393 |
|
|
|
|
|
|
|
|
|
|
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Apr 2023 to Apr 2024